Underperformance in the Dispensing Pharmacy Business Due to Revisions to the Medical Fee Schedule, etc.
First written in FY2017-Q1. 1 of 33 entries say "Materialised", first in 2026-08-06. Latest entry: 2026-08-06.
Vital Ksk Holdings moved to the "Worse" side of this theme in 2026, the same year as the typical company in this theme.
1 other company's latest entry also says "Materialised".
- 2026-08-06MaterialisedFinancial results
「In the pharmacy business, although the number of prescriptions received declined, sales increased slightly due to efforts including increasing revenue from dispensing technical fees and pharmaceutical management fees. Profit declined despite efforts to earn dispensing fees related to the family pharmacy function and manage costs, due in part to the impact of the dispensing fee and drug price revisions. As a result, sales were ¥4,894 million, up 101.1% year on year, and the segment loss (operating loss) was ¥60 million, compared with segment income of ¥42 million in the same period of the previous year.」
Records that the pharmacy business moved from segment income in the previous year to a segment loss due to the impact of the drug price revision and other factors. - FY2026Full-year pharmacy operations: results and slight profit growthAnnual report
「Although the number of prescriptions received declined, revenue from external customers was ¥19,960 million, compared with ¥19,552 million in the previous fiscal year, as a result of efforts including expanding dispensing fee revenue and medication management fee revenue. Segment profit was ¥252 million, compared with ¥251 million in the previous fiscal year, as a result of efforts to generate dispensing fees related to family pharmacy functions and manage costs.」
Despite the decline in prescriptions, revenue increased and profit edged up through higher dispensing fees and medication management fees, the generation of fees related to family pharmacy functions, and cost management. - FY2026-H1Interim pharmacy business performance: higher revenue and profitAnnual report
「In the pharmacy business, although the number of prescriptions received declined, revenue increased as a result of efforts including expanding dispensing fee revenue and medication management fee revenue. Profit also increased as a result of efforts to generate dispensing fees related to family pharmacy functions and manage costs.」
Despite the pharmacy business's previous trend of lower profit due to drug price revisions and other factors, interim profit increased through the generation of dispensing fees related to family pharmacy functions and cost management. - FY2025Full-year pharmacy business performance: higher revenue, lower profitAnnual report
「Although the number of prescriptions received declined, revenue from external customers was ¥19,552 million, compared with ¥19,115 million in the previous fiscal year, as a result of efforts including expanding dispensing fee revenue and medication management fee revenue. Profit declined, however, with segment profit at ¥251 million, compared with ¥310 million in the previous fiscal year, due to the impact of drug price revisions and longer prescription periods.」
The pharmacy business generated higher revenue, while profit declined due to drug price revisions and longer prescription periods. - FY2025-H1Interim pharmacy business performance: higher revenue, lower profitAnnual report
「In the pharmacy business, although the number of prescriptions received declined, revenue increased as a result of efforts including expanding dispensing fee revenue and medication management fee revenue. Profit declined, however, due to the impact of drug price revisions and longer prescription periods. As a result, revenue was ¥9,725 million, or 103.6% of the previous interim consolidated accounting period, and segment profit (operating profit) was ¥96 million, or 83.7% of the previous interim consolidated accounting period.」
Pharmacy business revenue increased, while segment profit declined due to drug price revisions and longer prescription periods. - FY2024Full-year pharmacy operations results; profit growthAnnual report
「In pharmacy operations, the number of stores increased by 1 through a business acquisition in August 2023. In addition, efforts were made to increase dispensing technical fee revenue and pharmaceutical management fee revenue, while the number of prescriptions received increased due to higher foot traffic following the reclassification of COVID-19 under the Infectious Diseases Control Law to Category 5, among other factors. As a result, revenue from external customers was ¥19,115 million, compared with ¥18,361 million in the previous fiscal year, and segment profit increased to ¥310 million, compared with ¥106 million in the previous fiscal year, due to the effect of higher revenue and a substantial decline in amortization of goodwill.」
The FY2024 full-year results for pharmacy operations have been updated. Revenue and profit increased due to the addition of 1 store, an increase in prescriptions received, and a decline in amortization of goodwill. - FY2024-Q3Third-quarter pharmacy operations results; profit growthAnnual report
「In pharmacy operations, the number of stores increased by 1 through a business acquisition in August 2023. In addition, efforts were made to increase dispensing technical fee revenue and pharmaceutical management fee revenue, while the number of prescriptions received increased due to higher foot traffic following the reclassification of COVID-19 under the Infectious Diseases Control Law to Category 5, among other factors. As a result, revenue was ¥14,295 million, compared with ¥13,769 million in the same period of the previous year. Segment profit (operating profit) increased to ¥259 million, compared with ¥77 million in the same period of the previous year, due to the effect of higher revenue and a substantial decline in amortization of goodwill.」
The cumulative third-quarter results for pharmacy operations have been updated. Revenue and profit increased due to the addition of 1 store through a business acquisition, an increase in prescriptions received, and a decline in amortization of goodwill. - FY2024-Q2Second-quarter pharmacy operations results; recoveryAnnual report
「In pharmacy operations, the number of stores increased by 1 through a business acquisition. In addition, efforts were made to increase dispensing technical fee revenue and pharmaceutical management fee revenue, while the number of prescriptions received increased due to higher foot traffic following the reclassification of COVID-19 under the Infectious Diseases Control Law to Category 5, among other factors. As a result, revenue was ¥9,386 million, compared with ¥9,009 million in the same period of the previous year. Segment profit (operating profit) increased to ¥114 million, compared with ¥32 million in the same period of the previous year, due to the effect of higher revenue and a substantial decline in amortization of goodwill.」
Pharmacy operations reported higher revenue and profit due to the addition of 1 store through a business acquisition, an increase in prescriptions received, and a decline in amortization of goodwill. - FY2024-Q1First-quarter pharmacy operations results; recoveryAnnual report
「In pharmacy operations, efforts were made to increase dispensing technical fee revenue and pharmaceutical management fee revenue. In addition, the number of prescriptions received increased due to higher foot traffic following the reclassification of COVID-19 under the Infectious Diseases Control Law to Category 5, among other factors. As a result, revenue was ¥4,654 million, compared with ¥4,481 million in the same period of the previous year. Segment profit (operating profit) increased to ¥87 million, compared with ¥14 million in the same period of the previous year, due to the effect of higher revenue and a substantial decline in amortization of goodwill.」
The situation has been updated from weak pharmacy operations due to previous drug price revisions and other factors to higher revenue and profit in the first quarter, driven by increased foot traffic and prescriptions following the Category 5 reclassification. - FY2023Full-year segment results updated; profit declinedAnnual report
「In pharmacy operations, efforts were made to calculate the relevant dispensing fees with the aim of becoming the family pharmacy sought by the government. However, due to the impact of the drug price revision, revenue from external customers was ¥18,361 million, down 0.2% from the previous consolidated fiscal year, and segment profit was ¥106 million, down 48.1%.」
Pharmacy operations reported lower revenue and profit due to the impact of the drug price revision, despite continued efforts toward becoming a family pharmacy. - FY2022Full-year segment results; turned profitableAnnual report
「In pharmacy operations, revenue from external customers was ¥18,397 million, up 9.7% from the previous consolidated fiscal year, due to the addition of 1 consolidated company and an increase in prescriptions received compared with the previous consolidated fiscal year. Segment profit was ¥205 million, compared with a segment loss of ¥19 million in the previous consolidated fiscal year.」
Pharmacy operations reported higher revenue due to the increase in consolidated companies and prescriptions received, turning from a loss in the previous year to profit of ¥205 million. - FY2022-Q3Third-quarter pharmacy operations results updated; turned profitableAnnual report
「In pharmacy operations, revenue was ¥13,791 million (110.4% year on year) due to the addition of 1 consolidated company and an increase in prescriptions received compared with the previous year. Segment profit (operating profit) was ¥162 million, compared with a segment loss of ¥37 million in the same period of the previous year.」
Pharmacy operations reported higher revenue due to the increase in consolidated companies and prescriptions received, turning from a loss in the same period of the previous year to profit of ¥162 million. - FY2022-Q2Second-quarter pharmacy operations results updated; turned profitableAnnual report
「In pharmacy operations, revenue was ¥9,045 million (109.8% year on year) due to the addition of 1 consolidated company and an increase in prescriptions received compared with the previous year. Segment profit (operating profit) was ¥83 million, compared with a segment loss of ¥44 million in the same period of the previous year.」
Pharmacy operations reported higher revenue due to the increase in consolidated companies and prescriptions received, turning from a segment loss in the same period of the previous year to profit of ¥83 million. - FY2022-Q1First-quarter segment results updated; turned profitableAnnual report
「In pharmacy operations, revenue was ¥4,437 million (108.9% year on year) due to the addition of 1 consolidated company and an increase in prescriptions received compared with the previous year. Segment profit (operating profit) was ¥39 million, compared with a segment loss of ¥70 million in the same period of the previous year.」
Pharmacy operations reported higher revenue due to the increase in consolidated companies and prescriptions received, turning from a segment loss in the same period of the previous year to profit of ¥39 million. - FY2021Full-year segment results updated; impact of COVID-19Annual report
「In Other businesses, revenue was ¥20,829 million, up 7.5% from the previous consolidated fiscal year, due to the addition of 1 consolidated company in pharmacy operations. However, profitability deteriorated at subsidiaries operating sports-related facilities and other entities due to the impact of COVID-19, resulting in a segment loss of ¥169 million, compared with a segment loss of ¥18 million in the previous consolidated fiscal year.」
The full-year results for Other businesses have been updated. Revenue increased due to the addition of consolidated companies, while the loss widened due to the impact of COVID-19. - FY2021-Q3Third-quarter segment results updated; impact of COVID-19Annual report
「In Other businesses, revenue was ¥22,604 million (104.8% year on year) due to the addition of 1 consolidated company in pharmacy operations. However, segment profit (operating profit) was ¥166 million (72.1% year on year) due to the impact of COVID-19.」
Other businesses reported higher revenue due to the increase in consolidated companies, while segment profit declined to 72.1% of the same period of the previous year due to the impact of COVID-19. - FY2021-Q2Semiannual segment results updated; impact of COVID-19Annual report
「In Other businesses, revenue was ¥14,873 million (101.9% year on year) due to the addition of 1 consolidated company in pharmacy operations. However, segment profit (operating profit) was ¥32 million (15.0% year on year) due to the impact of COVID-19.」
Other businesses reported higher revenue due to the increase in consolidated companies, while segment profit declined to 15.0% of the same period of the previous year due to the impact of COVID-19. - FY2021-Q1First-quarter segment results updated; business deterioratedAnnual report
「In Other businesses, revenue was ¥7,564 million (103.5% year on year) due to the addition of 1 consolidated company in pharmacy operations. However, segment loss (operating loss) was ¥31 million due to the impact of COVID-19, compared with segment profit of ¥85 million in the same period of the previous year.」
Other businesses reported higher revenue due to the increase in consolidated companies, but turned from profit in the same period of the previous year to a loss of ¥31 million due to the impact of COVID-19. - FY2020Full-year segment results updated; profit recoveredAnnual report
「As pharmacy operations and wholesale animal pharmaceuticals recovered, revenue from external customers was ¥29,093 million, up 2.8% from the previous consolidated fiscal year, and segment profit was ¥334 million, up 181.3%.」
Revenue and segment profit for Other businesses exceeded the previous year due to the recovery in pharmacy operations and wholesale animal pharmaceuticals. - FY2020-Q3Quarterly segment results updated; business recoveredAnnual report
「In Other businesses, revenue was ¥21,561 million (102.9% year on year), and segment profit (operating profit) was ¥230 million, as pharmacy operations and wholesale animal pharmaceuticals recovered, compared with a segment loss of ¥31 million in the same period of the previous year.」
Other businesses turned from a loss of ¥31 million in the same period of the previous year to profit of ¥230 million, as pharmacy operations and wholesale animal pharmaceuticals recovered. - FY2020-Q2Semiannual segment results updated; business recoveredAnnual report
「In Other businesses, revenue was ¥14,601 million (105.8% year on year), and segment profit (operating profit) was ¥213 million, as pharmacy operations and wholesale animal pharmaceuticals recovered, compared with a segment loss of ¥93 million in the same period of the previous year.」
Other businesses turned from a segment loss of ¥93 million in the same period of the previous year to profit of ¥213 million, as pharmacy operations and wholesale animal pharmaceuticals recovered. - FY2020-Q1Quarterly segment results updated; business recoveredAnnual report
「In Other businesses, revenue was ¥7,309 million (102.8% year on year), and segment profit (operating profit) was ¥85 million, as pharmacy operations and wholesale animal pharmaceuticals recovered, compared with a segment loss of ¥32 million in the same period of the previous year.」
Other businesses turned from a segment loss of ¥32 million in the same period of the previous year to profit of ¥85 million, as pharmacy operations and wholesale animal pharmaceuticals recovered. - FY2019Full-year segment results updated; profit declinedAnnual report
「In Other businesses, revenue was ¥28,312 million (98.5% year on year), and segment profit was ¥118 million (49.9% year on year), due to weak agricultural chemicals and pharmacy operations affected by the revision of medical fees.」
The full-year results for Other businesses have been updated. Revenue and segment profit fell below the same period of the previous year due to weak agricultural chemicals and pharmacy operations. - FY2019-Q3Quarterly segment results updated; business deterioratedAnnual report
「② Other businesses In Other businesses, revenue was ¥20,956 million (98.1% year on year), and the segment loss (operating loss) was ¥31 million, compared with segment profit of ¥158 million in the same period of the previous year, due to weak pharmacy operations and other businesses affected by the revision of medical fees.」
Other businesses turned from profit of ¥158 million in the same period of the previous year to a loss of ¥31 million due to weak pharmacy operations and other businesses affected by the revision of medical fees. - FY2019-Q2Semiannual segment results updated; business deterioratedAnnual report
「In Other businesses, revenue was ¥13,800 million (96.9% year on year), and the segment loss (operating loss) was ¥93 million, compared with segment profit of ¥64 million in the same period of the previous year, due to weak agricultural chemicals and pharmacy operations affected by the revision of medical fees.」
Other businesses turned from profit in the same period of the previous year to a loss of ¥93 million due to weak agricultural chemicals and pharmacy operations affected by the revision of medical fees. - FY2019-Q1Quarterly segment results updated; business deterioratedAnnual report
「② Other businesses In Other businesses, revenue was ¥7,107 million (96.0% year on year), and the segment loss (operating loss) was ¥32 million, compared with segment profit of ¥35 million in the same period of the previous year, due to weak wholesale agricultural chemicals and pharmacy operations affected by the revision of medical fees.」
The situation changed from the recovery in pharmacy operations indicated in the previous full year and immediately preceding quarter. Other businesses turned from profit in the same period of the previous year to a loss due to weak wholesale agricultural chemicals and pharmacy operations affected by the revision of medical fees. - FY2018Full-year segment results updated; business recoveredAnnual report
「In Other businesses, revenue was ¥28,750 million (99.8% year on year), due mainly to lower revenue from wholesale animal pharmaceuticals, while segment profit (operating profit) was ¥238 million, as pharmacy operations recovered (256.0% year on year).」
The full-year results for Other businesses have been updated. Revenue from wholesale animal pharmaceuticals declined, while profit increased due to the recovery in pharmacy operations. - FY2018-Q3Quarterly segment results updated; business recoveredAnnual report
「② Other businesses In Other businesses, revenue was ¥21,365 million (99.1% year on year), due mainly to lower revenue from wholesale animal pharmaceuticals, while segment profit (operating profit) was ¥158 million, as pharmacy operations recovered (269.0% year on year).」
The results have been updated to reflect an increase in segment profit to ¥158 million for Other businesses, as pharmacy operations recovered despite lower revenue from wholesale animal pharmaceuticals. - FY2018-Q2Semiannual segment results updated; business recoveredAnnual report
「② Other businesses In Other businesses, revenue was ¥14,235 million (98.3% year on year), due mainly to lower revenue from wholesale animal pharmaceuticals, while segment profit (operating profit) was ¥64 million, as pharmacy operations recovered, compared with a segment loss of ¥33 million in the same period of the previous year.」
Other businesses turned from a loss in the same period of the previous year to segment profit of ¥64 million, as pharmacy operations recovered despite lower revenue from wholesale animal pharmaceuticals. - FY2018-Q1Quarterly segment results updatedAnnual report
「② Other businesses In Other businesses, revenue was ¥7,400 million (98.2% year on year) due to the recovery in pharmacy operations, and segment profit (operating profit) was ¥35 million, compared with a segment loss of ¥29 million in the same period of the previous year.」
Other businesses turned from a segment loss in the same period of the previous year to segment profit of ¥35 million, as pharmacy operations recovered. - FY2017Update to full-year segment resultsAnnual report
「In Other businesses, wholesale animal pharmaceuticals performed well, but pharmacy operations were weak due to the impact of the revision of medical fees and other factors. Accordingly, revenue was ¥28,796 million (98.7% year on year), and segment profit was ¥93 million (33.3% year on year).」
The FY2017 full-year results for Other businesses have been updated. Wholesale animal pharmaceuticals performed well, while profit declined due to weak pharmacy operations. - FY2017-Q2Update to half-year resultsAnnual report
「In Other businesses, wholesale animal pharmaceuticals performed well, but pharmacy operations were weak due to the impact of the revision of medical fees and other factors. Accordingly, revenue was ¥14,480 million (102.3% year on year), and the segment loss (operating loss) was ¥33 million, compared with segment profit of ¥83 million in the same period of the previous year.」
The results have been updated to reflect a segment loss in the first half for Other businesses due to weak pharmacy operations, despite some strength in wholesale animal pharmaceuticals. - FY2017-Q1First statedAnnual report
「In Other businesses, wholesale animal pharmaceuticals performed well, but pharmacy operations were weak due to the impact of the revision of medical fees and other factors. Accordingly, revenue was ¥7,540 million (103.8% year on year), and the segment loss (operating loss) was ¥29 million, compared with segment profit of ¥29 million in the same period of the previous year.」
Wholesale animal pharmaceuticals performed well, but pharmacy operations were weak due to the revision of medical fees and other factors, resulting in a segment loss for Other businesses.